MedPath

Melatonin in ADHD and Sleep Problems

Phase 4
Recruiting
Conditions
Attention Deficit Hyperactivity Disorder
Sleep Disorder
Interventions
Registration Number
NCT04318067
Lead Sponsor
Allan Hvolby
Brief Summary

Treatment with melatonin is often initiated on an insufficient basis as it has not been established prior to starting the treatment whether or not the child had delayed release of endogenous melatonin. At the clinic, it has furthermore been observed that the length of time a child experiences an effect of melatonin treatment varies substantially.

In a clinical context, treatment with melatonin is used increasingly (www.Medstat.dk). However, there is no tradition in Denmark for measuring the endogenous melatonin level before initiating such treatment. Hence there is no way of knowing to what extent the sleep problems were indeed caused by delayed melatonin release.

There seem to be no studies on the difference in the effect of melatonin treatment of children and adolescents depending on whether or not they have delayed DLMO. Likewise, there are no studies including adolescents.

As can be seen, it is important to gain more knowledge about the normal release of melatonin, and the release of melatonin in a group of children and adolescents with a variety of psychiatric diagnoses. It is also essential to investigate whether there are any differences in the release of melatonin in children and adolescents with chronic sleep onset problem and children and adolescents who do not have sleep problems.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Children aged 6-13 years referred to the child and adolescent psychiatric department for examination/treatment for ADHD
  • Verified Cronical Sleep Problems
  • Measured Dim Light Melatonin Onset
Exclusion Criteria
  • IQ below 70
  • Autism Disorder
  • Actual or former treated with Melatonin
  • Allergy to melatonin

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Sleep problems i Attention Deficit Hyperactivity DisorderMelatonin 3 mgChildren age 6 to 12 years having ADHD and Sleeping problem will be treated with Melatonin 3 mg one a day (before bedtime)
Primary Outcome Measures
NameTimeMethod
Sleep onset6 month

Time where child falls asleep

Sleep onset Latency (SOL)6 month

How long time does the child use falling asleep after lights out

Total Sleep time6 month
Secondary Outcome Measures
NameTimeMethod
Dundee Difficult Times of the Day Scale (D-DTODS)6 month

On a 4 point Likert scale (1-4) the instrument asses the impact on Child and Family Self-Esteem and Quality of Life . Total max is 40 points and indicates low QoL and Minimum score is 10 and indicate Normal functioning and High QoL

Weiss Functional Impairment Rating Scale (WFIRS)6 month

Evaluation on different Quality of Life (QoL) scores. 50 Question Measuring QoL in School, Family setting and Social activities on a 4 Point Likert Scale (0-3) with af total max score om 150 (minimum 0) - A higher score is more difficulties and lower Quality of Life

Attention Deficit Hyperactivity Disorder - Scale Score (ADHD-RS)6 month

A Scale Score measuring ADHD symptoms on a 4 point Likert Scale (0-3) . 18 Question with a Total max score of 54, Total minimum Score is 0 . Higher score is more symptoms.

Side effect Rating Scale6 month

Registration of 17 known possible Side Effekts on a Likert Scale 0-9 point each, With a total score of 153 points which indicate many and serious Side effect and a minimum of 0 , which indicate Zero side effects

Trial Locations

Locations (1)

Child and Adolescent Psychiatric department

🇩🇰

Esbjerg, Denmark

© Copyright 2025. All Rights Reserved by MedPath